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ABSTRACT
Objectives Lupus T cells demonstrate aberrant DNA
methylation patterns dominated by hypomethylation
of interferon-regulated genes. The objective of this
study was to identify additional lupus-associated
DNA methylation changes and determine the genetic
contribution to epigenetic changes characteristic of
lupus.
Methods Genome-wide DNA methylation was assessed
in naïve CD4+ T cells from 74 patients with lupus and 74
age-matched, sex-matched and race-matched healthy
controls. We applied a trend deviation analysis approach,
comparing methylation data in our cohort with over 16
500 samples. Methylation quantitative trait loci (meQTL)
analysis was performed by integrating methylation
profiles with genome-wide genotyping data.
Results In addition to the previously reported
epigenetic signature in interferon-regulated genes, we
observed hypomethylation in the promoter region of
the miR-17-92 cluster in patients with lupus. Members
of this microRNA cluster play an important role in
regulating T cell proliferation and differentiation.
Expression of two microRNAs in this cluster, miR-19b1
and miR-18a, showed a significant positive correlation
with lupus disease activity. Among miR-18a target genes,
TNFAIP3, which encodes a negative regulator of nuclear
factor kappa B, was downregulated in lupus CD4+ T
cells. MeQTL identified in lupus patients showed overlap
with genetic risk loci for lupus, including CFB and IRF7.
The lupus risk allele in IRF7 (rs1131665) was associated
with significant IRF7 hypomethylation. However, <1% of
differentially methylated CpG sites in patients with lupus
were associated with an meQTL, suggesting minimal
genetic contribution to lupus-associated epigenotypes.
Conclusion The lupus defining epigenetic signature,
characterised by robust hypomethylation of interferon-
regulated genes, does not appear to be determined
by genetic factors. Hypomethylation of the miR-17-92
cluster that plays an important role in T cell activation is
a novel epigenetic locus for lupus.

INTRODUCTION

Systemic lupus erythematosus (lupus or SLE) is a
heterogeneous autoimmune disease of incompletely
understood aetiology. The disease is characterised
by a loss of immunotolerance and the development of autoantibodies against nuclear antigens.
Severe manifestations of lupus have significant

WHAT IS ALREADY KNOWN ON THIS TOPIC
⇒ Lupus is characterised by robust DNA
hypomethylation in interferon-regulated genes;
however, the genetic contribution to the lupus-
associated epigenotype is unknown.
WHAT THIS STUDY ADDS
⇒ Our results suggest that genetic factors do not

significantly contribute to the lupus-associated
DNA methylation profiles.
⇒ We also report a novel epigenetic locus for
lupus in a microRNA cluster involved in T cell
function.
⇒ Furthermore, we provide a prototype example
showing how a lupus risk genetic variant might
mediate functional pathogenic effects through
altering DNA methylation levels.
HOW THIS STUDY MIGHT AFFECT RESEARCH,
PRACTICE AND/OR POLICY
⇒ This study highlights the importance of non-
genetic factors in determining epigenetic
changes characteristic of lupus.
impact on quality of life and can lead to organ
damage and mortality in affected patients, particularly among patients of non-
European genetic
ancestry.1 2 Genetic risk contributes to the development of lupus, but the estimated heritability of lupus
is ~30%.3–5 Indeed, monozygotic twin studies in
lupus suggest a substantial non-genetic contribution
to the aetiology of lupus.6 Environmental exposures
across the lifespan that can directly impact epigenetic regulation and cellular function are suggested
to be involved in the pathogenesis of lupus.7 8
DNA methylation is an epigenetic mechanism
that regulates gene expression through the enzyme-
mediated addition of a methyl group to the cytosine
bases in the genome. DNA methylation is heritable
across cell generations and can promote gene
silencing, making it an important component in
regulating the plasticity of immune cell identity and
function.9 Early work demonstrated that adoptive
transfer of CD4+ T cells treated ex vivo with DNA
methyltransferase (DNMT) inhibitors was sufficient
to cause lupus-like disease in mice,10 mimicking the
DNA methylation inhibition in patients with drug-
induced lupus.11 Since then, other studies have
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observed that CD4+ T cells of patients with lupus show a distinct
shift in global DNA methylation compared with healthy individuals, potentially in part due to defective MEK/ERK signalling, suppressing DNA methyltransferase 1 (DNMT1) activity in
CD4+ T cells, and leading to hypomethylation and overexpression of costimulatory genes.12–16
We have previously observed a robust hypomethylation
signature in interferon-regulated genes defining patients with
lupus.17 18 Our initial findings in CD4+ T cells were subsequently confirmed and expanded to other cell types by our
group and others.19–21 In CD4+ T cells, we observed hypomethylation in interferon-regulated genes at the naïve CD4+ T cell
stage, preceding transcriptional activity. This epigenetic ‘poising’
or ‘priming’ of interferon-
regulated genes was independent
of disease activity.18 The genetic contribution to this lupus-
associated epigenotype is currently unknown.
Methylation quantitative trait loci (meQTL) are genetic polymorphisms that are associated with the methylation state of
CpG sites either through direct nucleotide change within the
CpG dinucleotide or intermediary mechanisms. Prior studies of
patients with lupus show an enrichment of meQTL associated
with type I interferon genes, genetic risk loci and specific clinical manifestations in whole blood and neutrophils.22–24 Furthermore, our previous work suggests that meQTL might at least in
part explain differences in DNA methylation between African-
American and European-American patients with lupus.22
Herein, we evaluated genome-wide DNA methylation data in
naïve CD4+ T cells from a large cohort of patients with lupus
compared with matched healthy controls. We integrated DNA
methylation and genotyping data to better understand the
influence of genetic factors on the DNA methylation changes
observed in lupus.

METHODS
Study participants and demographics

Seventy-four female patients with lupus and 74 female healthy
age-
matched (±5 years) and race-
matched controls were
recruited as previously described25 26 (online supplemental table
1). All patients fulfilled the American College of Rheumatology
classification criteria for SLE.27

Sample collection, DNA isolation and data generation

Genomic DNA samples for this study were collected from naïve
CD4+ T cells as previously described.18 Briefly, magnetic beads
and negative selection was used to isolate naïve CD4+ T cells
from whole blood samples collected from patients with lupus
and controls. Genomic DNA was directly isolated from collected
cells and bisulfite converted using the EZ DNA Methylation Kit
(Zymo Research, Irvine, California, USA). The Illumina HumanMethylation450 BeadChip (Illumina, San Diego, California,
USA) was used to measure DNA methylation levels at over 485
000 methylation sites across the genome.

Epigenome-wide association study

Epigenome-
wide association study (EWAS) for identifying
associations between specific CpG sites and disease status was
performed using GLINT.28 29 Covariates for age, race and technical batch were included for the analysis prior to other preprocessing. No outliers beyond 4 SD were detected in the first two
components of the principal component analysis (PCA) space,
all 148 samples were included in the analysis. Reference-less cell
type composition correction was performed using ReFACTor,
with six components used in the downstream analysis to account
2

for any cell-type heterogeneity in the samples. An additional
covariate was included to account for effects of genetic admixture using the EPISTRUCTURE algorithm included in GLINT.
Cell-
type composition covariate components generated by
ReFACTor were included at this step to reduce bias from potential cell-type heterogeneity, and polymorphic CpG sites were
excluded from this step and the EWAS. Using the age, race and
technical batch covariates, along with six ReFACTor components and one EPISTRUCTURE component, logistic regression
for disease status was performed across all CpG sites, excluding
the polymorphic and unreliable cross-reactive probes previously
described in the literature, as well as CpG sites with low variance
(SD <0.01).30 31

Differential DNA methylation analysis of gene promoters

Raw .idat files were used to generate methylation beta value
profiles across all samples using GenomeStudio (Illumina) after
background subtraction and normalising to internal control
probes. Missing probe values were imputed using sklearn.impute.
KNNImputer, and ComBat was used to correct for batch effects
associated with sample preparation.32–34 Ensembl gene loci for
hg19 were downloaded using PyEnsembl.35 For each gene, loci
for 1500 base pairs upstream of the transcription start site36 to
the transcription start site (TSS) were mapped to the overlapping
CpG probes using PyBedtools, and the mean of the associated
probes for each gene was used as the representative methylation value for the resulting 20 437 mapped genes.37 Differential methylation analysis comparing patients and controls was
performed on the mean TSS1500 methylation using limma, and
false discovery rate adjustment using the Benjamini-Hochberg
method was used to correct p values for multiple testing. Gene
Ontology Enrichment for Biological Process terms was performed
on the differentially methylated gene list using Enrichr with the
mapped promoter gene list used as the background.38 39

Trend deviation analysis

DNA methylation data derived using the Illumina 450k methylation array from 23 415 samples were downloaded from Gene
Expression Omnibus (GEO).40 To reduce batch effects, samples
from experiments with fewer than 50 samples were omitted,
and the remaining samples were quantile normalised.41 A matrix
of pairwise Pearson’s correlation values for DNA methylation
levels was computed across TSS1500 gene promoters in 16
541 samples across 37 tissues to create a multitissue correlation network (online supplemental figure 1). The differentially
methylated genes in lupus-naïve CD4+ T cells were clustered by
their correlation in global signature created from the GEO data.
Hierarchical clustering was performed using Scipy’s hierarchical
linkage. Kyoto Encyclopedia of Genes and Genomes (KEGG)
enrichment analysis was performed using Enrichr,42 and p values
were reported after false discovery rate (FDR) adjustment.
The goal of a trend deviation analysis is to detect correlation
patterns among differentially methylated genes in large DNA
methylation datasets. A correlation in methylation among a set
of differentially methylated genes between patients and controls
suggests a trend is being observed, reinforcing the significance
and robustness of the differential DNA methylation detected
between patients and controls.

Genotyping

Genomic DNA isolated from naïve CD4+ T cells was used as input
for the Infinium Global Screening Array-
24 V.2.0 (Illumina).
Single nucleotide polymorphisms (SNPs) with a genotyping call
Coit P, et al. Ann Rheum Dis 2022;0:1–10. doi:10.1136/annrheumdis-2022-222656
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rate <98%, minor allele frequencies (MAF) <5% and deviating
from Hardy-Weinberg equilibrium (p<1E-3) were filtered out.
Samples were removed if they had a genotyping call rate <95%.
Sex chromosomes were not analysed. About 100 000 independent SNPs were pruned and used to perform PCA with Eigensoft (V.6.1.4) software.43 Genotyping data were analysed using
PLINK (V.1.9).44 Genotype profiles were generated for n=63
patients and n=68 controls.

Methylation quantitative trait loci analysis

Raw .idat files were used to generate methylation profiles
using minfi (V.1.32.0)45 46 and to check median intensity values
and reported sex in the R statistical computing environment
(V.3.6.3).47 Probes with less than three beads and zero intensity
values across all samples were removed using the DNAmArray
package (V.0.1.1).48 Background signal and dye bias were
corrected, followed by normalisation of signal intensities using
functional normalisation in the preprocessFunnorm.DNAmArray
function48 49 using the first three principal component values
calculated from signal intensities of control probes present on
all array spots to correct for technical variation. Any probe with
a detection p<0.01 or returned signal intensities in fewer than
98% of samples was removed. This resulted in a total of 476
767 probes used for further analysis. Signal intensities were
then converted to M values with a maximum bound of ±16.
M values were used for meQTL analysis and converted to beta
values (0%–100% methylation scale) using minfi for reporting.
We removed any probe for meeting any of the following technical criteria: a unique probe sequence of <30 bp, mapping to
multiple sites in the genome, polymorphisms that cause a colour
channel switching in type I probes, inconsistencies in specified
reporter colour channel and extension base, mapping to the Y
chromosome and/or having a polymorphism within 5 bp of the
3’ end of the probe with a MAF >1% with the exception of
CpG-SNPs with C>T polymorphisms which were retained.50
Batch correction for chip ID was performed using the ComBat
function in the sva (V.3.34.0) package.51 After technical filtering,
there were a total of 421 214 probes used for meQTL analysis.
We implemented a mixed correspondence analysis with the
PCAmixdata package (V.3.1)52 to calculate eigenvalues using
patient medication data for prednisone, hydroxychloroquine,
azathioprine, mycophenolate mofetil and cyclophosphamide.
The top four components accounted for a cumulative 89.3%
of variability in the medication data. Each component value
was used as an independent variable in regression analysis to
adjust for medication usage across individuals. MeQTL association analysis was performed in patients and controls separately
using methylation M value profiles and corresponding sample
genotypes. Age, the top 4 medication components and top 10
genotype principal components were included as covariates to
build a linear model for detecting meQTL using MatrixEQTL
(V.2.3).53 Cis-meQTL were defined as CpG sites with methylation values associated with an SNP within a conservative 1000 bp
of the CpG dinucleotide. We used a Benjamini-Hochberg FDR-
adjusted p value cut-off of <0.05 as a threshold for significant
associations. The above EWAS results were compared with the
meQTL results to determine overlap of lupus-associated differentially methylated CpG sites and those CpG sites in an meQTL.

Functional enrichment analysis

ToppGene Suite was used for functional enrichment analysis54
of Molecular Function and Biological Process Gene Ontologies
and KEGG pathways in meQTL. P values were derived using
Coit P, et al. Ann Rheum Dis 2022;0:1–10. doi:10.1136/annrheumdis-2022-222656

a hypergeometric probability mass function, and a Benjamini-
Hochberg FDR-
adjusted p value cut-
off of <0.05 was used
as a threshold of significance. A minimum membership of 3
genes and maximum of 2000 genes in each term was used as a
threshold for inclusion. Interferon-regulated genes were identified using the set of genes associated with the CpG site in each
meQTL as input using Interferome (V.2.01).55 The type I interferon response genes were defined as genes with an expression
fold change of 1.5 or greater between type I interferon-treated
and untreated samples using gene expression datasets from all
available CD4+ T cell experiments in the Interferome database.
For the analysis of miR-18a-regulated genes, literature-based
network association analysis was performed using IRIDESCENT
to create a weighted network of published relationships as previously described.56

MicroRNA expression microarray

MicroRNA (miRNA) expression was measured in naïve CD4+ T
cells from a subset of patients with lupus and healthy matched
controls (n=16). Cells were immediately lysed with TRIzol
Reagent (ThermoFisher Scientific, New York, USA) followed by
storage at −80°C. Total RNA was isolated using the Direct-zol
RNA MiniPrep Kit (Zymo Research, California, USA) following
the manufacturer’s directions. The Affymetrix miRNA V.4.1
Array Strip (Affymetrix, California, USA) was used to measure
expression of over 2000 premature and 2500 mature human
miRNA sequences. RNA sequences were polyadenylated and
ligated to a biotin-labelled oligomer using the FlashTag Biotin
HSR RNA Labeling Kit (Affymetrix). Biotin-labelled sequences
were hybridised to array probes and washed then stained with
streptavidin-
phycoerythrin (PE). The Affymetrix Expression
Console & Transcriptome Analysis Console V.2.0 software
(Affymetrix) was used to analyse biotin/streptavidin-PE fluorescence measurements. All samples passed signal intensity, polyadenylation and ligation quality controls. Signal intensities were
background adjusted and normalised. Log2-transformed expression values for each probeset was calculated using a robust multi-
array average model.23 The Pearson’s r correlation coefficient
for median expression values of probes for miR-17, miR-18a,
miR-19a, miR-19b1 and miR-20a and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores were calculated
using GraphPad Prism (V.9.3.0) (GraphPad Software, California,
USA).

RESULTS
Differential methylation of gene promoters in naïve CD4+ T
cells isolated from patients with lupus

A comparison of DNA methylation profiles from circulating
naïve CD4+ T cells isolated from 74 patients with lupus and
74 age-
matched, sex-
matched and race-
matched healthy
controls revealed a total of 2627 CpGs, out of 334 337 total
CpG sites included in the EWAS, with a significant difference in
average methylation. Significant hypomethylation in interferon-
regulated genes was observed, consistent with previous reports
(online supplemental table 2). Average promoter methylation for
each gene was calculated by including all CpG sites on the array
within 1500 bp of the associated gene’s TSS. A total of 51 genes
showed a significant difference in average promoter methylation
between patients with lupus and controls (17 hypomethylated
and 34 hypermethylated in patients compared with controls)
(table 1) (figure 1). Biological Process Gene Ontology enrichment analysis of differentially methylated promoter regions did
not show significant enrichment compared with the background
3
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Table 1 Genes with differentially methylated promoter regions
in naive CD4+ T cells of patients with lupus compared with healthy
controls
Gene

Δβ

−log10 (FDR-adjusted p value)

t-statistic

IFI44L

−0.177

Infinity

−10.757

DTX3L

−0.130

Infinity

−11.566

BST2

−0.089

11.323

−9.285

RABGAP1L

−0.088

9.165

−8.421

BCL2L14

−0.086

5.520

−6.908

MIR19B1

−0.059

3.169

−5.846

IFI44

−0.059

2.057

−5.304

MIR20A

−0.055

3.088

−5.807

MIR17

−0.054

6.882

−7.487

MIR18A

−0.051

6.537

−7.342

MIR19A

−0.049

4.771

−6.579

IKZF4

−0.048

3.289

−5.902

MX1

−0.046

10.624

−9.004

TRIM34

−0.045

2.184

−5.367

ODF3B

−0.034

1.712

−5.128

GNG2

−0.033

2.138

−5.344

FAM177B

−0.025

1.897

−5.223

MZF1

0.008

1.493

5.014

SSBP4

0.015

1.344

4.934

ATP6V0D1

0.018

2.594

5.569

DCUN1D1

0.025

2.068

5.309

C14orf93

0.025

1.922

5.236

TIPARP

0.026

2.069

5.310

LMBRD1

0.027

2.211

5.381

HAVCR2

0.027

2.574

5.560

KIAA1949

0.030

3.158

5.841

GPD2

0.032

1.953

5.251

CNTF

0.033

1.705

5.124

CD47

0.034

4.259

6.350

ARHGAP9

0.036

3.339

5.926

IL27RA

0.036

1.367

4.946

RAP1A

0.036

2.573

5.559

LAMA3

0.037

1.445

4.988

ABI3

0.037

1.436

4.983

FAM102A

0.038

3.161

5.842

CXCR5

0.039

1.439

4.985

DPEP2

0.040

1.889

5.219

DYRK2

0.041

3.924

6.197

TMEM71

0.044

2.757

5.649

ADORA2A

0.046

2.234

5.392

SEPT9

0.047

2.036

5.293

PSMB4

0.052

2.935

5.734

TOM1

0.055

5.415

6.862

PRIC285

0.057

9.934

8.729

LTB

0.062

2.036

5.293

MIR1205

0.067

1.698

5.121

ACER3

0.073

2.612

5.578

BCL9L

0.079

4.034

6.248

MDS2

0.080

3.149

5.836

SNORA5B

0.083

1.712

5.128

PTPRCAP

0.091

3.620

6.057

FDR correction was performed using the Benjamini-Hochberg method with an
FDR-adjusted p value threshold of <0.05. Δβ: methylation difference in median
methylation value of CpG sites within 1500 bp upstream of the associated gene’s
transcription start site (TSS1500) between patients with lupus and healthy controls.
FDR, false discovery rate; TSS, transcription start site.

4

Figure 1 Distribution of average CpG methylation levels within 1500
bp of the transcription start site (TSS1500) for the respective genes
differentially methylated (DM) in naïve CD4+ T cells of patients with
lupus compared with healthy controls.
of all gene promoters after adjusting for multiple testing (online
supplemental table 3).
The pairwise correlation of the 51 gene promoters identified
above was calculated across a collection of 16 541 samples from
37 tissues available in GEO. Hierarchical clustering of correlations showed that 21 out of the 51 gene promoters were highly
Coit P, et al. Ann Rheum Dis 2022;0:1–10. doi:10.1136/annrheumdis-2022-222656
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Table 2 KEGG pathway gene enrichment of 21 gene promoters highly correlated with each other in multitissue DNA methylation data
constructed from 16 541 samples available through Gene Expression Omnibus
Pathway (KEGG_2019_Human)

P value

FDR-adjusted, p value

OR

Genes

MicroRNAs in cancer

1.21E-05

0.00039

20.92

MIR19B1;MIR20A;MIR17;MIR18A;MIR19A

Cytokine-cytokine receptor interaction

0.0034

0.043

11.28

CNTF;CXCR5;LTB

Rheumatoid arthritis

0.0041

0.043

23.52

LTB;ATP6V0D1

FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes; OR, odds ratio.

correlated. KEGG pathway enrichment analysis showed a significant enrichment for three pathways among the 21 correlated
gene promoters: ‘microRNAs in cancer’ (p=3.86E-
04),
cytokine receptor interaction’ (p=4.34E-
02) and
‘cytokine-
‘rheumatoid arthritis’ (p=4.34E-02) (table 2) (figure 2). The
‘microRNAs in cancer’ pathway included genes encoding miR-
17, miR-18a, miR-19a, miR-19b1 and miR-20a. Four of seven
CpG sites used to calculate the average promoter methylation
(TSS1500) in this locus showed a significant reduction in median
methylation in patients with lupus compared with healthy
controls (figure 3A). These sites: cg17799287 (Δβ=−5.5%;
p=2.05E-03), cg07641807 (Δβ=−4.4%; p=1.71E-02),
cg23665802 (Δβ=−5.8%; p=1.19E-02) and cg02297838
(Δβ=−4.9%; p=3.48E-02) were all hypomethylated in patients
with lupus compared with healthy controls, and overlapped with
enhancers and regions flanking TSS in peripheral naïve CD4+ T
cells using data collected from the Epigenome Roadmap57 and
visualised using the WashU Epigenome Browser.58 We examined
expression levels of the miRNAs included in the ‘microRNAs
in cancer’ pathway (miR-17, miR-18a, miR-19a, miR-19b1 and
miR-20a) in naïve CD4+ T cells of a subset of our patients with
lupus (n=16) and healthy matched controls (n=16). We did not
observe a difference in expression between patients and controls.
However, two miRNAs, miR-18a-5p and miR-19b1-5p, showed
a significant positive correlation (hsa-miR-18a-5a p=0.038 and
hsa-miR-19b1-5p p=0.042) between median expression levels
and SLEDAI scores in patients with lupus (figure 3B) (online
supplemental table 4).
Examining publicly available miRNA expression data from
total CD4+ T cells revealed overexpression of miR-
18a in
patients with lupus compared with healthy control individuals.59

Figure 2 Heatmap of hierarchical clustering of pairwise Pearson’s
correlation coefficient values of 51 differentially methylated gene
promoters (transcription start site (TSS)1500) in global tissue signature
derived from 16 541 samples. Range from +1 (red) to −1 (blue),
represent a greater to lower correlation in global tissue, respectively.
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways are
significantly enriched (false discovery rate-adjusted p<0.05) in a block
of 21 genes (green bars).
Coit P, et al. Ann Rheum Dis 2022;0:1–10. doi:10.1136/annrheumdis-2022-222656

In these same samples, a total of 74 miR-18a-target genes were
downregulated in patients with lupus compared with controls.
Using a literature-based network association analysis, we identified 15 of these 74 genes with relatedness to lupus (online
supplemental figure 2). TNFAIP3, which encodes a negative
regulator of nuclear factor kappa B (NF-κB) targeted by miR-
18a, was downregulated in lupus CD4+ T cells compared with
controls.
We examined the expression of MIR17HG, which is the host
gene that encodes the miR-17-92 cluster, in single cell RNA-
sequencing data from lupus nephritis tissue samples generated
by the Accelerating Medicines Partnership (AMP) project.60 We
show evidence for MIR17HG mRNA expression in multiple
immune cells infiltrating the kidneys of patients with lupus
nephritis, including multiple T cell subsets, although in a
small percentage of kidney infiltrating cells. While over 8% of
tissue-resident macrophages in lupus nephritis tissues express

Figure 3 (A) Violin plots of the seven CpG sites in patients with
lupus and healthy controls used to calculate the average promoter
methylation (transcription start site (TSS)1500) for the miR-17-92
cluster. The solid black bar represents the median value and the dashed
lines the first and third quartiles. Genomic visualisation and annotation
are from WashU Epigenome Browser using AuxillaryHMM tracks from
peripheral naïve CD4+ T cells (E038 and E039, top and bottom tracks,
respectively). n.s., not significant. *P<0.05, **p<0.01. (B) Correlation of
median microRNA (miRNA) expression in naïve CD4+ T cells of a subset
(n=16) of patients with lupus with Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI) score. Hsa-miR-18a-5p and hsa-miR-
19b1-5p had a Pearson’s correlation (r) of 0.52 (p=0.038) and 0.51
(p=0.042), respectively.
5

Ann Rheum Dis: first published as 10.1136/annrheumdis-2022-222656 on 16 June 2022. Downloaded from http://ard.bmj.com/ on August 19, 2022 at Henry Ford Hospital. Protected by
copyright.

Systemic lupus erythematosus

Figure 4 Proportion of differentially methylated CpG sites in naïve
CD4+ T cells of patients with lupus compared with healthy controls
associated with a methylation quantitative trait loci (meQTL) in (A)
patients with lupus, (B) healthy controls and (C) the subset of meQTL
shared between patients with lupus and healthy controls.
MIR17HG mRNA, the highest levels of expression were
observed in T cell subsets (online supplemental figure 3).

Naïve CD4+ T cell methylation quantitative trait loci in
patients with lupus

pathways related to tissue growth and development (‘animal
organ morphogenesis’; p=8.44E-10, ‘urogenital system development’; p=1.05E-07) and gene silencing (‘negative regulation
of gene silencing by miRNA’; p=2.54E-6, ‘negative regulation of
post-transcriptional gene silencing’; p=5.41E-6) (online supplemental table 9).
We compared our list of meQTL in patients with lupus with
previously identified lupus susceptibility loci from genome-wide
association studies.4 61–64 We found 41 meQTL with CpG site-
associated genes that overlapped with 20 unique lupus risk loci
genes (online supplemental table 10). This included interferon
regulatory factor genes IRF5 and IRF7. We found three meQTL
in naïve CD4+ T cells that included, or were in high linkage
disequilibrium (LD) (r2 ≥0.80) with, a known lupus genetic risk
variant (table 3).65 We also performed a similar analysis using
data previously collected from granulocytes of patients with
lupus to determine if these effects were present across tissues.22
We found meQTL associated with lupus risk variants in CFB
(rs170942) and IRF7 (rs1131665) in both naïve CD4+ T cells
and granulocytes isolated from patients with lupus. In addition, an meQTL associated with the TMEM86B-PTPRH locus
was observed in naïve CD4+ T cells. When we compared the
lupus risk alleles with DNA methylation levels, we found that
the presence of the risk allele at rs1270942 (CFB) is associated
with increased DNA methylation of cg16505946. The presence
of the risk allele at rs1131665 (IRF7) (figure 5) and rs56154925
(TMEM86B-PTPRH) was associated with decreased DNA methylation of cg16486109 and cg01414877, respectively. The direction of the risk allele-DNA methylation association in the CFB
and IRF7 meQTL was the same in both naïve CD4+ T cells and
granulocytes.
We examined the overlap between genes associated with CpG
sites in meQTLin lupuspatients and genes that respond to type
I interferon treatment in CD4+ T cells, to better understand the
association between genetics and type I interferon-response gene
methylation differences in lupus. A total of 101 unique type I
interferon-response genes were identified as meQTL in our data
(online supplemental table 11).
Because IRF7 is a master regulator of type I interferon
response,66 and the lupus-associated epigenotype is dominated
by hypomethylation in interferon-regulated genes, we examined
if rs1131665 (IRF7) had an effect on the methylation levels of
the 2627 CpGs differentially methylated in naïve CD4+ T cells
between patients with lupus and healthy controls. This trans-
meQTL analysis revealed no significant difference in methylation levels across these CpG sites based on rs1131665 genotypes,
among patients with lupus (analysis of variance, data not shown).

Global genotype profiles were generated in a subset of patients
and controls and compared with global DNA methylation
profiles to identify CpG sites with allele-specific methylation
associations. There was no significant difference in the average
age (years) between the patient (n=63) and control (n=68)
subsets (patient average age=41.6; patient age SD=12.8; control
average age=40.8; control age SD=12.5; t-test statistic=0.381;
two-tailed p=0.704). Allele-specific DNA methylation associations were measured as meQTL, where the CpG site was within
1000 bp of the measured SNP separately in patients and controls.
After adjusting for age, genetic background and medication use
in patients, we identified 5785 meQTL in naïve CD4+ T cells
of patients with lupus with an FDR-adjusted p<0.05 (online
supplemental table 5). These meQTL include 4649 unique CpG
sites and 4120 unique polymorphisms.
A linear model adjusting for age and genetic background
was fit to healthy controls separately. We identified a total of
7331 meQTL with an FDR-adjusted p<0.05 in controls (online
supplemental table 6). These meQTL include 5885 unique CpG
sites and 5138 unique polymorphisms.
Of 2627 CpG sites differentially methylated between patients
and controls, we identified 17 (0.65%) and 34 (1.29%) CpG
sites that overlapped with CpG sites included in meQTL in
patients and controls, respectively (figure 4A,B). We examined the overlap of meQTL in patients with lupus and healthy
controls and identified a total of 3957 meQTL (68.4% of lupus
patient meQTL and 54.0% of healthy control meQTL) shared
between both patients and controls (online supplemental table
7). This shared set of meQTL contained 8 (0.3%) CpG sites that
we identified as differentially methylated between patients with
lupus and controls (figure 4C).
Functional enrichment analysis was performed using genes
associated with CpG sites in our meQTL shared between patients
and controls. Functional enrichment analysis revealed multiple
ontologies and pathways for cell adhesion (‘cell-cell adhesion’;
p=1.04E-12, ‘biological adhesion’; p=6.80E-12, ‘cell adhesion’; p=8.25E-12, ‘cell adhesion molecules’; p=2.25E-06),
transporter associated with antigen processing (TAP) proteins
and antigen presentation (‘TAP binding’; p=1.59E-7, ‘peptide
antigen binding’; p=4.40E-5) and immune disorder pathways
(‘type I diabetes mellitus’; p=1.92E-8, ‘graft-versus-host disease
(GVHD)’; p=4.38E-7) (online supplemental table 8).
There were 1828 meQTL detected only in patients with lupus
but not in controls. These were enriched in gene ontologies and

We generated genome-
wide DNA methylation data in naïve
CD4+ T cells from a large cohort of patients with lupus and
matched healthy controls. Implementing an innovative trend
deviation analysis, we identified a cluster of miRNAs (miR-17,
miR-18a, miR-19a, miR-19b1, miR-20a) among differentially
methylated loci in patients with lupus. Promoter methylation
analysis revealed significant hypomethylation in this miRNA
cluster in patients with lupus compared with controls. Trend
deviation analysis suggested a coordinated, disease-
associated
change in promoter methylation for these miRNAs. Indeed,
the expression of miR-18a and miR-19b1 included within this
cluster positively correlated with disease activity, as measured
using SLEDAI score, in our patients with lupus.
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Table 3

MeQTL in naive CD4+ T cells and granulocytes of patients with lupus that include a known lupus risk variant

Lupus-naïve CD4+ T cell meQTL
CpG site

meQTL SNP

Lupus risk SNP*

Risk SNP-associated gene

Lupus risk allele

Direction of CpG methylation associated with risk allele

cg16505946

rs558702

rs1270942

CFB

C

↑

cg16486109

rs1131665

rs1131665

IRF7

A

↓

cg01414877

rs56154925

rs56154925

TMEM86B-PTPRH

C

↓

Lupus granulocyte meQTL
CpG site

meQTL SNP

Lupus risk SNP*

Risk SNP-associated gene

Lupus risk allele

Direction of CpG methylation associated with risk allele

cg16505946

rs558702

rs1270942

CFB

C

↑

cg16486109

rs1131665

rs1131665

IRF7

A

↓

*rs558702 and rs1270942 have an LD r2 ≥0.80.
meQTL, methylation quantitative trait loci; SNP, single nucleotide polymorphism.

MiRNAs play an important role in post-transcriptional gene
regulation by targeting specific complementary gene transcripts
for degradation.67 Peripheral blood cells in patients with lupus
show altered expression of miRNAs.68 Some dysregulated
miRNAs in lupus target DNMT1, and as a result, contribute to
altered DNA methylation patterns in lupus CD4+ T cells.69–71
miR-17, miR-18a and miR-20a form the ‘miR-17 family’ while
miR-19a and miR-19b1 form the ‘miR-19 family’. These miRNAs
are grouped by sequence homology and encoded in a single polycistronic miRNA gene as the ‘miR-17-92 cluster’. This cluster has
been well-studied as an oncogene and an immune regulator.72
Average promoter methylation of miR-17, miR-18a, miR-19a,
miR-19b1 and miR-20a was reduced by ~5% in patients with
lupus compared with controls, which has not been previously
described in immune cells of patients with lupus. Enterovirus
71 infection has been observed to suppress miR-17-92 cluster
expression by increasing DNMT-mediated promoter methylation,73 and chemical inhibition of DNMT1 activity in bleomycin-
induced lung fibrosis mouse model increases miR-17-92 cluster
expression in lung fibroblasts.74 This suggests that miR-17-92
cluster promoter methylation plays an important role in regulating the expression of its members.
MiR-17-92 cluster genes play a vital role in regulating T cell
activities including proliferation and differentiation. Overexpression of miR-17-92 cluster genes promotes lymphoproliferative

Figure 5 (A) Gene structure diagram of IRF7 depicting the location
of rs1131665 and cg16486109. (B) The presence of the lupus risk allele
at rs1131665 (allele A) is associated with significantly lower DNA
methylation levels of cg16486109 located in IRF7. FDR, false discovery
rate; TSS, transcription start site.
Coit P, et al. Ann Rheum Dis 2022;0:1–10. doi:10.1136/annrheumdis-2022-222656

disease and autoimmunity in mice by targeting critical immunotolerance regulators Bim and PTEN.75 Conditional knockout
of miR-
17-
92 cluster in a murine model of chronic GVHD
(cGVHD) reduced disease-associated T cell infiltration and IgG
deposition in the skin.76 In cGVHD mice, miR-17-92 cluster
expression in CD4+ T cells supports T helper (Th)1, Th17
and T follicular helper (Tfh) cell differentiation. Loss of miR-
17-
92 cluster expression leads to a corresponding reduction
in Tfh-dependent germinal centre formation and plasma cell
differentiation.76 MiR-17, miR-18a, miR-19a and miR-20a are
overexpressed in splenic T cells of MRL/lpr mice.77 Similarly,
miR-17, miR-17a, miR-18a, miR-19a, miR-19b1 and miR-20a
are overexpressed in circulating CD4+ T cells of patients with
lupus.78 MiR-
19b1 expression, specifically, has a significant
positive correlation with disease activity as measured by SLEDAI
score.78 MiR-17 and miR-20 are downregulated in circulating
peripheral blood mononuclear cells,79 B cells80 and as circulating
free miRNAs81 in patients with lupus compared with healthy
controls, suggesting tissue-specific and miRNA-specific expression patterns. Of the miR-17-92 cluster miRNAs identified as
differentially methylated in our analysis, only miR-18a and miR-
19b1 showed a significant positive correlation between median
expression in naïve CD4+ T cells and disease activity in patients
with lupus, consistent with these prior observations. MiR-19b1
promotes proliferation of mature CD4+ T cells, Th1 differentiation and interferon-γ production, and suppresses inducible Treg
differentiation.82 MiR-18a expression increases rapidly early on
in CD4+ T cell activation,83 84 and suppresses Th17 cell differentiation through direct targeting of critical Th17 transcription factor transcripts including SMAD4, HIF1A and RORA in
human CD4+ T cells in vitro and in vivo murine airway inflammation models.83 We did not observe a difference in the expression of members in the miR-17-92 cluster between patients with
lupus and controls in naïve CD4+ T cells, likely because these
miRNAs are upregulated upon T cell activation. Evidence for
hypomethylation in lupus in naïve CD4+ T cells suggests epigenetic priming of this locus, similar to what we previously observed
in interferon-regulated gene loci in lupus.18
Consistent with our DNA methylation data and the epigenetic
priming concept in naïve CD4+ T cells discussed above, gene
expression data in total CD4+ T cells isolated from patients with
lupus compared with normal healthy controls revealed upregulation of miR-18a in lupus and concomitant downregulation
of several genes known to be targeted by miR-18a.59 Of 74
miR-18a target genes downregulated in lupus CD4+ T cells, our
literature-based analysis highlighted 15 genes, including HIF1A
which is involved in T cell differentiation as discussed above.
The most robustly lupus-
related gene was TNFAIP3, which
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encodes the NF-κB negative regulator A20. Indeed, the genetic
association between TNFAIP3 loss-of-function polymorphisms
and lupus has been repeatedly confirmed.85
Single cell RNA sequencing data from lupus nephritis kidney
tissues revealed evidence for expression of MIR17HG, the host
gene encoding the miR-
17-
92 cluster, in kidney-
infiltrating
immune cells, including multiple T cell subsets. Further studies
are needed to determine if altered DNA methylation at the miR-
17-92 cluster promoter is associated with expression changes
with a causal role in the development of lupus, and to determine
if methylation levels at this locus can be used as biomarker for
monitoring disease activity.
We used analysis of meQTL to identify allele-specific DNA
methylation associations across the genome of naïve CD4+ T
cells from patients with lupus and healthy controls. Our primary
objective was to understand to what extent are DNA methylation changes associated with lupus (the lupus-defining epigenetic
profile), explained by genetic factors. We found that <1% of
differentially methylated sites in patients with lupus compared
with healthy controls were associated with a cis-meQTL. This
suggests that almost all of the DNA methylation alterations
observed in lupus are not associated with local allelic differences in the genome, suggesting a greater contribution from
genetic and possibly environmental factors to epigenetic
non-
dysregulation in lupus. A previous study of meQTL in whole
blood of patients with lupus found that a majority of meQTLs
were shared between patients and controls.24 We observed that
about 68% of meQTL in patients with lupus and 54% of meQTL
in healthy controls were shared by both groups, supporting this
observation.
Our prior analysis of granulocytes from a cohort of
patients with lupus identified overlap in meQTL genes
and lupus genetic risk loci.22 MeQTL pairs including
ARID5B
(cg13344587-rs10821936),
HLA-DQB1
(cg13047157-rs9274477), and IRF7 (cg16486109-rs1131665)
were found in both granulocytes and naïve CD4+ T cells from
patients with lupus. Risk loci genes unique to naïve CD4+ T
cell meQTLs included CD80 (cg06300880-rs3915166), TYK2
(cg06622468-rs280501), IKBKE (cg22577136-rs17020312) and
CTLA4 (cg05092371-rs16840252, cg05092371-rs4553808).
Naïve CD4+ T cell-specific meQTL risk loci genes are related
to signal response and activation in CD4+ T cells compared
with the more general DNA repair and type I interferon signalling seen in the shared meQTL risk loci genes. Disease-relevant
meQTL show tissue-specific patterns which should be considered when teasing apart their potential impact.
We identified three meQTL that include SNPs previously
identified as lupus genetic risk variants. One meQTL is in the
complement factor B gene CFB (cg16505946-rs558702), where
the risk allele is associated with increased DNA methylation of
the nearby CpG site. Complement factor B (CFB) combines
with C3 to form the C3 convertase after cleavage by complement factor D as part of the alternative complement pathway.
Complement pathway defects have long been studied as a model
of monogenic lupus and contribute to increased risk of polygenic lupus.65 We identified an additional meQTL that included
a known lupus risk variant in IRF7 (cg16486109-rs1131665).
Rs1131665 is a missense variant in the inhibitory domain of
IRF7 (Q412R). This lupus-associated amino acid change was
demonstrated to enhance IRF7-induced expression response in
a luciferase reporter assay.86 This same risk allele is also associated with decreased DNA methylation of cg16486109. Although
the relative DNA methylation fractions are different between
naïve CD4+ T cells and granulocytes of patients with lupus, the

direction of the allele-specific DNA methylation is the same.
This suggests that the observed meQTL effect may be present
in other lymphoid and myeloid tissues, potentially including
plasmacytoid dendritic cells, which are major producers of type
I interferons. We describe a direct association between a lupus
risk allele and local hypomethylation of a CpG site in IRF7 in
lupus. This observation provides new insights regarding possible
biological mechanisms underlying pathogenic consequences of
lupus-associated genetic polymorphisms.
In summary, we investigated genome-
wide DNA methylation changes in naïve CD4+ T cells from an extended cohort of
patients with lupus and controls, and using a methylation trend
deviation analysis method, we showed promoter hypomethylation of the miR-17-92 cluster that has a significant regulatory
role in T cell growth, function and differentiation. Combining
genome-wide DNA methylation and genotyping data, we were
able to determine genetic contribution to the lupus-defining epigenotype. Our data indicate that epigenetic changes characteristic
of lupus are not under direct genetic influence. This suggests a
more important role for non-genetic factors in the epigenetic
dysregulation observed in patients with lupus, including the
robust demethylation of interferon-regulated genes.
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